Physician profile
Peter M Sutherland
NPI 1396795480
$3,240.10
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $495 · 2021: $793 · 2022: $418 · 2023: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $703.45 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $593.45 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $338.20 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.88 | 2019-2022 | |
| Amgen INC. | $217.53 | 2019-2023 | Otezla, Repatha |
| Abbvie INC. | $212.79 | 2021-2022 | |
| Pfizer INC. | $184.39 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $95.00 | 2019-2021 | |
| Astellas Pharma US INC | $79.58 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $64.14 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $63.49 | 2021-2023 | Camzyos, Eliquis |
| Allergan, INC. | $62.23 | 2019-2020 | |
| Lilly USA, LLC | $60.47 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $53.87 | 2019-2023 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $37.04 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $36.76 | 2021 | |
| Merck Sharp & Dohme LLC | $30.81 | 2022-2023 | Pneumovax 23, Vaxneuvance, Vaxelis |
| Dexcom, INC. | $30.58 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.81 | 2023 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $20.30 | 2019 | |
| Abbott Laboratories | $18.71 | 2019 | |
| Inogen, INC. | $17.86 | 2022 | |
| Biogen, INC. | $17.50 | 2021 | |
| Corium, LLC | $17.38 | 2022 | |
| Mylan Specialty L.P. | $14.26 | 2019 | |
| Amarin Pharma, INC. | $12.94 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.